SB1280 would add a new consumer protection provision to Hawaii law aimed at preserving access to the federal 340B drug discount program. The bill finds that 340B savings help nonprofit hospitals, rural hospitals, community health centers, Native Hawaiian health centers, and Ryan White program participants provide affordable medications and community health services, especially in geographically isolated parts of the state. It states that manufacturer restrictions on contract pharmacy arrangements can reduce patient access and undermine the financial stability of safety-net providers.
The bill would prohibit 340B covered entities in Hawaii from entering contracts with drug manufacturers, wholesale distributors, or their affiliates if those contracts directly or indirectly restrict the use of contract pharmacies to dispense 340B drugs, unless federal law prohibits that arrangement. It would also void certain contract provisions for drugs sold under a maximum allowable cost reimbursement model if that model was already in effect on or before June 30, 2025. The measure authorizes the attorney general to bring civil actions to enforce these requirements.
Impact
SB1280 would amend chapter 481B, Hawaii Revised Statutes, by creating a new state-law restriction on drug manufacturer and distributor contracting practices affecting 340B entities. It would give covered entities a statutory basis to challenge contract terms that limit contract pharmacy access and would invalidate certain maximum allowable cost provisions, while also expanding enforcement authority to the attorney general. The bill would affect 340B hospitals, federally qualified health centers, Native Hawaiian health centers, Ryan White providers, pharmacies, drug manufacturers, and wholesale distributors operating in Hawaii.
Sentiment
The bill’s stated purpose and framing are strongly supportive of 340B providers and patient access, and the legislative findings describe the measure as a response to unfair manufacturer practices that harm consumers and rural communities. No committee transcripts or recorded votes were provided, so there is no additional evidence of debate, amendments, or divided sentiment in the available record. Based on the bill text alone, the overall tone is protective of healthcare access and critical of manufacturer restrictions.
Contention
The main point of contention is likely the bill’s limitation on private contracting practices by drug manufacturers and wholesale distributors, especially where those contracts restrict contract pharmacy use. Another likely issue is the voiding of contract provisions tied to the maximum allowable cost payment model, which could affect pharmacy reimbursement arrangements for generic drugs. Supporters are the covered entities and patients who rely on 340B savings and contract pharmacies, while potential opponents would be drug manufacturers, wholesalers, and possibly pharmacy benefit or reimbursement stakeholders concerned about contract freedom and pricing controls.